PROSPECTS OF COMPLEX USE OF PHARMACOLOGICAL NEUROPROTECTION AND VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN PATIENTS WITH MACULAR EDEMA WITH RETINAL VEIN OCCLUSION
https://doi.org/10.17238/PmJ1609-1175.2019.2.33-37
Abstract
Objective: to assess clinical effectiveness of complex use of ‘Lucentis’ and ‘Meldonium’ in the treatment of macular edema caused by retinal vein occlusion.
Methods: 35 patients (35 eyes) with macular edema with retinal vein occlusion were undergone three consecutive “load” intravitreal administrations of 0.5 mg (0.005 mL) of ‘Lucentis’ once a month. In 19 cases, the introduction of Lucentis was supplemented with daily parabulbar injections of 0.5 ml of Meldonium solution for 10 days.
Results: Using Meldonium visual acuity increased by 3.5 times, light sensitivity of the central zone of the retina – 2.1 times and electrical lability – 1.2 times. Visual electric threshold of retina decreased by 1.5 times.
Conclusions:The improvement of functional parameters in the combined treatment is due to the ability of Meldonium to activate the recovery of the chorioretinal microblood in the macula. The results of a clinical study on the reversibility of ischemic and metabolic injuries of the neuroreceptors of the macula in patients with macular edema with retinal vein occlusion allow us to recommend ‘Meldonium’ for the improvement of visual functions after the intravitreal administration of ‘Lucentis’.
About the Authors
L. P. Danilova
Khabarovsk branch of S.N. Fyodorov NMRC “MNTK “Eye Microsurgery”,
Postgraduate Institute for Public Health Workers
Russian Federation
Russian Federation
211 Tikhookeanskaya St. Khabarovsk 680033 Russian Federation
9 Krasnodarskaya St. Khabarovsk 680000 Russian Federation
V. V. Egorov
Khabarovsk branch of S.N. Fyodorov NMRC “MNTK “Eye Microsurgery”,
Postgraduate Institute for Public Health Workers
Russian Federation
Russian Federation
211 Tikhookeanskaya St. Khabarovsk 680033 Russian Federation
9 Krasnodarskaya St. Khabarovsk 680000 Russian Federation
G. P. Smoliakova
Khabarovsk branch of S.N. Fyodorov NMRC “MNTK “Eye Microsurgery”,
Postgraduate Institute for Public Health Workers
Russian Federation
Russian Federation
211 Tikhookeanskaya St. Khabarovsk 680033 Russian Federation
9 Krasnodarskaya St. Khabarovsk 680000 Russian Federation
D. A. Povalyaeva
Khabarovsk branch of S.N. Fyodorov NMRC “MNTK “Eye Microsurgery”
Russian Federation
Russian Federation
211 Tikhookeanskaya St. Khabarovsk 680033 Russian Federation
N. S. Zhaivoronok
Khabarovsk branch of S.N. Fyodorov NMRC “MNTK “Eye Microsurgery”
Russian Federation
Russian Federation
211 Tikhookeanskaya St. Khabarovsk 680033 Russian Federation
L. P. Emanova
Khabarovsk branch of S.N. Fyodorov NMRC “MNTK “Eye Microsurgery”
Russian Federation
Russian Federation
211 Tikhookeanskaya St. Khabarovsk 680033 Russian Federation
References
1. Budzinskaya M.V., Mazurina N.K., Egorov A.E. [et al.]. The algorithm of treatment patients with retinal vein occlusion. Report 3. Neovascular complications // Annals of Ophthalmology. 2015. No. 6. P. 67–75.
2. Astakhov Yu.S., Petrishchev N.N., Tultseva S.N. Retinal vein thrombosis: etiology, pathogenesis, clinic, diagnosis, treatment. St Petersburg: Pavlov First St. Petersburg State Medical University, 2005. 60 p.
3. Danilova L.P., Egorov V.V., Smoliakova G.P. [et al.]. Efficiency of functional rehabilitation of patients with degenerative myopia complicated by choroidal neovascularization, combined use of Ranibizumab and Retinalamin // Modern technologies in ophthalmology. 2016. No. 2. P. 97–101.
4. Budzinskaya M.V., Mazurina N.K., Egorov A.E. [et al.]. The algorithm of treatment patients with retinal vein occlusion. Report 3. Neovascular complications // Annals of Ophthalmology. 2015. No. 6. P. 67–75.
5. Egorov E.A., Astakhov Yu.S., Stavitskaya T.V. Ophthalmopharmacology. Moscow: GEOTAR-Media, 2009. 592 p.
6. Danilova L.P., Egorov V.V., Smoliakova G.P. [et al.]. Efficiency of functional rehabilitation of patients with degenerative myopia complicated by choroidal neovascularization, combined use of Ranibizumab and Retinalamin // Modern technologies in ophthalmology. 2016. No. 2. P. 97–101.
7. Kiseleva T.N. Ocular ischemic syndrome (clinic, diagnosis, treatment): Dissertation abstracts. Moscow, 2001. 32 p.
8. Egorov E.A., Astakhov Yu.S., Stavitskaya T.V. Ophthalmopharmacology. Moscow: GEOTAR-Media, 2009. 592 p.
9. Tultseva S.N., Astakhov Yu.S. Retinal vein occlusion (etiology, pathogenesis, clinic, diagnosis, treatment). St. Petersburg: N-L Publ., 2010. 112 p.
10. Kiseleva T.N. Ocular ischemic syndrome (clinic, diagnosis, treatment): Dissertation abstracts. Moscow, 2001. 32 p.
11. Tultseva S.N., Astakhov Yu.S. The role of inflammation in pathogenesis of postthrombotic macular edema. Modern directions of drug treatment // Ophthalmology Journal. 2012. Vol. 5, No. 4. P. 35–44.
12. Tultseva S.N., Astakhov Yu.S. Retinal vein occlusion (etiology, pathogenesis, clinic, diagnosis, treatment). St. Petersburg: N-L Publ., 2010. 112 p.
13. Schuko A.G., Zlobin I.V., Yurieva T.N. [et al.]. Imbalance of intraocular cytokines at retinal vein occlusion and its relationship with effectiveness of anti-angiogenic therapy // Annals of Ophthalmology. 2015. Vol. 131, No. 2. P. 50–58.
14. Tultseva S.N., Astakhov Yu.S. The role of inflammation in pathogenesis of postthrombotic macular edema. Modern directions of drug treatment // Ophthalmology Journal. 2012. Vol. 5, No. 4. P. 35–44.
15. Berger A.R., Cruess A.F., Altomare F. [et al.]. Optimal treatment of retinal vein occlusion: Canadian expert consensus // Ophthalmologica. 2015. Vol. 234, No. 1. P. 6–25.
16. Schuko A.G., Zlobin I.V., Yurieva T.N. [et al.]. Imbalance of intraocular cytokines at retinal vein occlusion and its relationship with effectiveness of anti-angiogenic therapy // Annals of Ophthalmology. 2015. Vol. 131, No. 2. P. 50–58.
17. Campochiaro P.A., Pearlman S.R., Brown D.M. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study // Ophthalmology. 2014. Vol. 121, No. 1. P. 209–219.
18. Berger A.R., Cruess A.F., Altomare F. [et al.]. Optimal treatment of retinal vein occlusion: Canadian expert consensus // Ophthalmologica. 2015. Vol. 234, No. 1. P. 6–25.
19. Ip M.S., Scott I.U. VanVeldhuisen P.C. [et al.]. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema decondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 // Arch. Ophthalmol. 2009. Vol. 127, No. 9. P. 1101–1114.
20. Campochiaro P.A., Pearlman S.R., Brown D.M. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study // Ophthalmology. 2014. Vol. 121, No. 1. P. 209–219.
21. Kanski J.J. Retinal venous occlusive disease // Clinical ophthalmology: A systematic approach, 6th ed. Edinburg; London: Butterworth-Heinemann ELSEVIER, 2007. P. 584–590.
22. Ip M.S., Scott I.U. VanVeldhuisen P.C. [et al.]. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema decondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 // Arch. Ophthalmol. 2009. Vol. 127, No. 9. P. 1101–1114.
23. Karia N. Retinal vein occlusion: pathophysiology and treatment options // Clin. Ophthalmol. 2010. No. 4. P. 809–816.
24. Kanski J.J. Retinal venous occlusive disease // Clinical ophthalmology: A systematic approach, 6th ed. Edinburg; London: Butterworth-Heinemann ELSEVIER, 2007. P. 584–590.
25. Pearse A.K., Srinivas R.S. Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab // Clin. Ophthalmol. 2011. No. 5. P. 771–781.
26. Karia N. Retinal vein occlusion: pathophysiology and treatment options // Clin. Ophthalmol. 2010. No. 4. P. 809–816.
27. Wong T.Y., Scott I.U. Clinical practice. Retinal-vein occlusion // N. Engl. J. Med. 2010. Vol. 363, No. 22. P. 2135–2144.
28. Pearse A.K., Srinivas R.S. Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab // Clin. Ophthalmol. 2011. No. 5. P. 771–781.
29. Wong T.Y., Scott I.U. Clinical practice. Retinal-vein occlusion // N. Engl. J. Med. 2010. Vol. 363, No. 22. P. 2135–2144.
Review
For citations:
Danilova L.P., Egorov V.V., Smoliakova G.P., Povalyaeva D.A., Zhaivoronok N.S., Emanova L.P. PROSPECTS OF COMPLEX USE OF PHARMACOLOGICAL NEUROPROTECTION AND VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN PATIENTS WITH MACULAR EDEMA WITH RETINAL VEIN OCCLUSION. Pacific Medical Journal. 2019;(2):33-37. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2019.2.33-37
Views:
328
Email this article 